Factor V Leiden Mutation in Venous Thrombosis in Southeast Turkey

Abstract

Venous thrombosis (VT) is a common disease, with an annual incidence in the general population of approximately 1 per 1,000. Factor V Leiden mutation (G1691A) (FVL) is the most common risk factor in venous thrombosis. The prevalence of FVL for thrombosis varies greatly in different regions of the world. FVL mutation has been identified both by conventional method and fluorescence resonance energy transfer (FRET) with the LightCycler. Sixty-one patients with VT, different in age and sex, were consecutively entered into this study to assess the prevalence of FVL in VT in southeast Turkey. FVL mutation was found in 24.6% (15/61). Fourteen individuals were heterozygous and 1 homozygous, a rate of 22.9% and 1.6%, respectively. In conclusion, the authors suggest that FVL mutation is common in patients with venous thrombosis in southeast Turkey.

Get full access to this article

View all access options for this article.

References

Rosendaal FR : Risk factors for venous thrombotic disease. Thromb Haemost 82:610-619, 1999.

Poort SR , Rosendaal FR , Reitsma PH , et al : A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88:3698-3703, 1996.

Dahlbäck B , Carlsson M , Svensson PJ : Familial thrombophilia due to previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 90:1004-1008, 1993.

Griffin JH , Evatt B , Wideman C , et al : Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood 82:1989-1993, 1993.

Rosendaal FR , Koster T , Vandenbroucke JP , et al : High risk of thrombosis in patients homozygous for factor V Leiden (Activated protein C resistance). Blood 85:1504-1508, 1995.

Hagstrom JN , Walter J , Langner RB , et al : Prevalence of the factor V Leiden mutation in children and neonates with thromboembolic disease. J Pediatr 133:771-781, 1998.

Bertina RM , Koeleman BPC , Koster T , et al : Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369:64-67, 1994.

Gregg JP , Yamane AJ , Grody WW : Prevalence of the factor V Leiden mutations in four distinct American ethnic populations. Am J Med Gen 73:334-336, 1997.

Ozbek U , Tangun Y : Frequency of factor V Leiden in Turkey. Int J Hematol 64:291-292, 1996.

10.

Rees DC , Cox M , Clegg JB : World distribution of factor V Leiden. Lancet 346:1133-1134, 1995.

11.

Koster T , Rosendaal FR , de Ronde H , et al : Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 342:1503-1506, 1993.

12.

Lay MJ , Wittwer CT : Real-time fluorescence genotyping of factor V Leiden during rapid-cycle PCR. Clin Chemist 43:2262-2267, 1997.

13.

Ridker PM , Hennekens CH , Lindpaintner K , et al : Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 332:912-917, 1995.

14.

Ridker PM , Miletich JP , Hennekens CH , et al : Ethnic distribution of factor V Leiden in 4,047 men and women. JAMA 277:1305-1307, 1997.

15.

Chaa WP , Lee CK , Kwong YL , et al : A novel mutation of Arg306 of factor V gene in Hong Kong Chinese. Blood 91:1135-1139, 1998.

16.

Gurgey A , Haznedaroglu IC , Egesel T , et al : Two common genetic thrombotic risk factors: Factor V Leiden and prothrombin G20210A in adult Turkish patients with thrombosis. Am J Hematol 67:107-111, 2001.

17.

Kalkanli S , Ayyildiz O , Tiftik N , et al : Factor V Leiden mutation in our region. XIX. National Gevher Nesibe Meeting, Congress and Workshop of Hematology-Oncology, Congress Book (Turkish). Nevsehir, Turkey, May 24-26, 2001, pp 106-106.